Single-molecule analysis of subtelomeres and telomeres in Alternative Lengthening of Telomeres (ALT) cells.

Alternative lengthening of telomeres (ALT) Cancer telomeres Genomics SK-MEL-2 Saos-2 Single molecule optical mapping U2OS

Journal

BMC genomics
ISSN: 1471-2164
Titre abrégé: BMC Genomics
Pays: England
ID NLM: 100965258

Informations de publication

Date de publication:
15 Jul 2020
Historique:
received: 12 05 2020
accepted: 08 07 2020
entrez: 17 7 2020
pubmed: 17 7 2020
medline: 19 3 2021
Statut: epublish

Résumé

Telomeric DNA is typically comprised of G-rich tandem repeat motifs and maintained by telomerase (Greider CW, Blackburn EH; Cell 51:887-898; 1987). In eukaryotes lacking telomerase, a variety of DNA repair and DNA recombination based pathways for telomere maintenance have evolved in organisms normally dependent upon telomerase for telomere elongation (Webb CJ, Wu Y, Zakian VA; Cold Spring Harb Perspect Biol 5:a012666; 2013); collectively called Alternative Lengthening of Telomeres (ALT) pathways. By measuring (TTAGGG) n tract lengths from the same large DNA molecules that were optically mapped, we simultaneously analyzed telomere length dynamics and subtelomere-linked structural changes at a large number of specific subtelomeric loci in the ALT-positive cell lines U2OS, SK-MEL-2 and Saos-2. Our results revealed loci-specific ALT telomere features. For example, while each subtelomere included examples of single molecules with terminal (TTAGGG) n tracts as well as examples of recombinant telomeric single molecules, the ratio of these molecules was subtelomere-specific, ranging from 33:1 (19p) to 1:25 (19q) in U2OS. The Saos-2 cell line shows a similar percentage of recombinant telomeres. The frequency of recombinant subtelomeres of SK-MEL-2 (11%) is about half that of U2OS and Saos-2 (24 and 19% respectively). Terminal (TTAGGG) n tract lengths and heterogeneity levels, the frequencies of telomere signal-free ends, and the frequency and size of retained internal telomere-like sequences (ITSs) at recombinant telomere fusion junctions all varied according to the specific subtelomere involved in a particular cell line. Very large linear extrachromosomal telomere repeat (ECTR) DNA molecules were found in all three cell lines; these are in principle capable of templating synthesis of new long telomere tracts via break-induced repair (BIR) long-tract DNA synthesis mechanisms and contributing to the very long telomere tract length and heterogeneity characteristic of ALT cells. Many of longest telomere tracts (both end-telomeres and linear ECTRs) displayed punctate CRISPR/Cas9-dependent (TTAGGG) n labeling patterns indicative of interspersion of stretches of non-canonical telomere repeats. Identifying individual subtelomeres and characterizing linked telomere (TTAGGG) n tract lengths and structural changes using our new single-molecule methodologies reveals the structural consequences of telomere damage, repair and recombination mechanisms in human ALT cells in unprecedented molecular detail and significant differences in different ALT-positive cell lines.

Sections du résumé

BACKGROUND BACKGROUND
Telomeric DNA is typically comprised of G-rich tandem repeat motifs and maintained by telomerase (Greider CW, Blackburn EH; Cell 51:887-898; 1987). In eukaryotes lacking telomerase, a variety of DNA repair and DNA recombination based pathways for telomere maintenance have evolved in organisms normally dependent upon telomerase for telomere elongation (Webb CJ, Wu Y, Zakian VA; Cold Spring Harb Perspect Biol 5:a012666; 2013); collectively called Alternative Lengthening of Telomeres (ALT) pathways. By measuring (TTAGGG) n tract lengths from the same large DNA molecules that were optically mapped, we simultaneously analyzed telomere length dynamics and subtelomere-linked structural changes at a large number of specific subtelomeric loci in the ALT-positive cell lines U2OS, SK-MEL-2 and Saos-2.
RESULTS RESULTS
Our results revealed loci-specific ALT telomere features. For example, while each subtelomere included examples of single molecules with terminal (TTAGGG) n tracts as well as examples of recombinant telomeric single molecules, the ratio of these molecules was subtelomere-specific, ranging from 33:1 (19p) to 1:25 (19q) in U2OS. The Saos-2 cell line shows a similar percentage of recombinant telomeres. The frequency of recombinant subtelomeres of SK-MEL-2 (11%) is about half that of U2OS and Saos-2 (24 and 19% respectively). Terminal (TTAGGG) n tract lengths and heterogeneity levels, the frequencies of telomere signal-free ends, and the frequency and size of retained internal telomere-like sequences (ITSs) at recombinant telomere fusion junctions all varied according to the specific subtelomere involved in a particular cell line. Very large linear extrachromosomal telomere repeat (ECTR) DNA molecules were found in all three cell lines; these are in principle capable of templating synthesis of new long telomere tracts via break-induced repair (BIR) long-tract DNA synthesis mechanisms and contributing to the very long telomere tract length and heterogeneity characteristic of ALT cells. Many of longest telomere tracts (both end-telomeres and linear ECTRs) displayed punctate CRISPR/Cas9-dependent (TTAGGG) n labeling patterns indicative of interspersion of stretches of non-canonical telomere repeats.
CONCLUSION CONCLUSIONS
Identifying individual subtelomeres and characterizing linked telomere (TTAGGG) n tract lengths and structural changes using our new single-molecule methodologies reveals the structural consequences of telomere damage, repair and recombination mechanisms in human ALT cells in unprecedented molecular detail and significant differences in different ALT-positive cell lines.

Identifiants

pubmed: 32669102
doi: 10.1186/s12864-020-06901-7
pii: 10.1186/s12864-020-06901-7
pmc: PMC7364475
doi:

Substances chimiques

DNA 9007-49-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

485

Subventions

Organisme : NHGRI NIH HHS
ID : R01 HG005946
Pays : United States
Organisme : NIH HHS
ID : R21HG007205 and R21CA177395
Pays : United States

Références

Bioessays. 2008 Jan;30(1):25-37
pubmed: 18081009
Cell. 2015 Feb 26;160(5):913-927
pubmed: 25723166
Cell. 2017 Jun 29;170(1):86-101.e16
pubmed: 28666128
Cancer Res. 2007 Aug 1;67(15):7072-7
pubmed: 17652140
Cancer Res. 2005 Apr 1;65(7):2730-7
pubmed: 15805272
Genome Res. 2017 Nov;27(11):1904-1915
pubmed: 29025896
Int J Urol. 1997 Jul;4(4):407-10
pubmed: 9256332
Nat Commun. 2017 Jan 24;8:14015
pubmed: 28117327
Genes Dev. 2015 Feb 1;29(3):322-36
pubmed: 25644606
EMBO Rep. 2011 Dec 23;13(1):52-9
pubmed: 22157895
Nat Biotechnol. 2012 Aug;30(8):771-6
pubmed: 22797562
Aging (Albany NY). 2012 Jun;4(6):379-92
pubmed: 22683684
Science. 1994 Dec 23;266(5193):2011-5
pubmed: 7605428
Neoplasia. 2013 Nov;15(11):1301-13
pubmed: 24339742
EMBO Rep. 2017 Jun;18(6):929-946
pubmed: 28500257
Nat Commun. 2019 Mar 4;10(1):1025
pubmed: 30833565
PLoS Genet. 2012;8(7):e1002772
pubmed: 22829774
Nat Genet. 2000 Dec;26(4):447-50
pubmed: 11101843
J Cell Biol. 2012 Dec 10;199(6):893-906
pubmed: 23229897
EMBO Rep. 2016 Dec;17(12):1731-1737
pubmed: 27760777
Ann Anat. 2010 Sep 20;192(5):284-91
pubmed: 20732797
Nature. 2000 Aug 10;406(6796):641-5
pubmed: 10949306
Science. 2012 May 4;336(6081):593-7
pubmed: 22556254
EMBO Rep. 2017 Jun;18(6):914-928
pubmed: 28487353
Cell. 2010 Apr 2;141(1):81-93
pubmed: 20371347
Nat Struct Mol Biol. 2015 Nov;22(11):875-80
pubmed: 26581522
Nucleic Acids Res. 2017 May 19;45(9):e73
pubmed: 28180280
Science. 2017 Feb 10;355(6325):638-641
pubmed: 28082411
Cell. 2009 Jul 10;138(1):90-103
pubmed: 19596237
Nat Rev Genet. 2010 May;11(5):319-30
pubmed: 20351727
Genes Dev. 2010 Apr 1;24(7):720-33
pubmed: 20360388
Nat Biotechnol. 2009 Dec;27(12):1181-5
pubmed: 19935656
Proc Natl Acad Sci U S A. 1990 Mar;87(5):1758-61
pubmed: 2308935
Nature. 2016 Nov 3;539(7627):54-58
pubmed: 27760120
PLoS Genet. 2020 Jan 27;16(1):e1008347
pubmed: 31986135
Nat Commun. 2014 Oct 21;5:5220
pubmed: 25330849
Science. 2015 Jan 16;347(6219):273-7
pubmed: 25593184
Cell. 1987 Dec 24;51(6):887-98
pubmed: 3319189
EMBO J. 2017 Oct 2;36(19):2907-2919
pubmed: 28877996
Mob Genet Elements. 2011 Jul;1(2):128-134
pubmed: 22016861
Trends Genet. 2017 Dec;33(12):921-932
pubmed: 28969871
EMBO J. 2007 Jun 6;26(11):2707-18
pubmed: 17491589
Nat Rev Mol Cell Biol. 2017 Mar;18(3):175-186
pubmed: 28096526
Genetics. 2016 Jan;202(1):351-62
pubmed: 26510793
Mutat Res. 2012 Feb 1;730(1-2):59-67
pubmed: 21663926
Cell. 2014 Sep 25;159(1):108-121
pubmed: 25259924
Mol Cell. 2007 Oct 26;28(2):315-27
pubmed: 17964269
Cold Spring Harb Perspect Biol. 2013 Jun 01;5(6):
pubmed: 23732473

Auteurs

Heba Z Abid (HZ)

School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, USA.

Jennifer McCaffrey (J)

School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, USA.

Kaitlin Raseley (K)

School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, USA.

Eleanor Young (E)

School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, USA.

Katy Lassahn (K)

School of Medical Diagnostic and Transnational Sciences, Old Dominion University, Norfolk, VA, USA.

Dharma Varapula (D)

School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, USA.

Harold Riethman (H)

School of Medical Diagnostic and Transnational Sciences, Old Dominion University, Norfolk, VA, USA. hriethma@odu.edu.

Ming Xiao (M)

School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, USA. ming.xiao@drexel.edu.
Institute of Molecular Medicine and Infectious Disease, School of Medicine, Drexel University, Philadelphia, PA, USA. ming.xiao@drexel.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH